<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00322699</url>
  </required_header>
  <id_info>
    <org_study_id>WBPDT-577-04</org_study_id>
    <nct_id>NCT00322699</nct_id>
  </id_info>
  <brief_title>Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer</brief_title>
  <official_title>Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Florida/South Georgia Veterans Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>North Florida Foundation for Research and Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Axcan Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>North Florida/South Georgia Veterans Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is evaluating efficacy and toxicity of three sequential whole bladder&#xD;
      photodynamic treatment with Photofrin and red laser light (630 nm) in the management of&#xD;
      superficial bladder cancer (non-muscle invasive) in those patients who have failed or are not&#xD;
      candidates for conventional intravesical therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient Evaluation and Treatment:&#xD;
&#xD;
        1. Patients will sign an IRB-approved informed consent form&#xD;
&#xD;
        2. Initial patient assessments will include:&#xD;
&#xD;
             -  eligibility&#xD;
&#xD;
             -  History and physical.&#xD;
&#xD;
             -  clinical profile&#xD;
&#xD;
             -  upper urinary tract imaging (if clinically indicated)&#xD;
&#xD;
             -  urinary symptoms assessment&#xD;
&#xD;
      WBPDT Treatment:&#xD;
&#xD;
        1. Porfimer Sodium (Photofrin) 1.5 mg/kg iv followed 2 days later by whole bladder laser&#xD;
           light at 630 nm with target light doses of 1200 Joules (+/-100Joules)&#xD;
&#xD;
        2. Patients will undergo three sequential WBPDT treatments&#xD;
&#xD;
        3. Treatments will occur at least three months apart&#xD;
&#xD;
        4. All WBPDT treatments will occur within 12 months&#xD;
&#xD;
           Decisions to administer a second or third WBPDT will be based upon urological and&#xD;
           medical assessment of the individual patient and not necessarily dependent upon Dose&#xD;
           Limiting Toxicities (DLT) or early stopping endpoints (although such information may be&#xD;
           taken into account in the individual patient assessment). Patients experiencing DLT may&#xD;
           continue WBPDT at the investigator's discretion at the same or reduced doses of Porfimer&#xD;
           Sodium and/or light.&#xD;
&#xD;
           The following will be considered Dose Limiting Toxicities (DLT):&#xD;
&#xD;
             -  Urinary symptoms grade 3, or more over 12 weeks duration (see section 7 for&#xD;
                toxicity grading)&#xD;
&#xD;
             -  Loss of &gt; 50% of baseline bladder volume&#xD;
&#xD;
             -  Clinical decision of investigator or patient to discontinue due to toxicity.&#xD;
&#xD;
           Efficacy will be assessed on the basis of the following criteria:&#xD;
&#xD;
             -  Complete Response: cystoscopy with biopsy and/or cytology without evidence of&#xD;
                cancer.&#xD;
&#xD;
             -  Partial Response: normal cystoscopy and biopsies, if obtained, but persistent&#xD;
                positive or suspicious cytology localized to the bladder; or, for patients with&#xD;
                CIS, &gt; 50% reduction in extent of CIS.&#xD;
&#xD;
             -  Persistent/Recurrent Disease: persistent or recurrent cancer of the same or lesser&#xD;
                stage and grade as at enrollment without obvious increase in tumor burden.&#xD;
&#xD;
             -  Progression: cancer of any greater stage or grade than at enrollment or obvious&#xD;
                increase in tumor burden.&#xD;
&#xD;
           Referred patients will undergo post-PDT cystoscopy by the referring Urologists, who will&#xD;
           transmit the results to the study site in Gainesville,Fl.&#xD;
&#xD;
        5. Symptoms will be assessed for one month following each WBPDT by weekly telephone&#xD;
           contact.&#xD;
&#xD;
        6. Urine and blood for cytokines will be obtained before each treatment and possibly twice&#xD;
           afterwards and stored -80oF for analysis later.&#xD;
&#xD;
        7. Biopsy specimen samples from tumor and normal bladder may be obtained at cystoscopy and&#xD;
           stored for later analysis for biomarkers.&#xD;
&#xD;
        8. Patients will be followed for toxicity, disease status, urinary tract symptoms, and&#xD;
           survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease progression</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Superficial Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>A single arm, non-randomized Phase II Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-Randomized Phase II,Single Arm Study evaluating the efficacy of whole bladder photodynamic therapy as an alternative to radical cystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Whole bladder laser light treatment as an alternative to radical cystectomy</intervention_name>
    <description>The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.</description>
    <arm_group_label>A single arm, non-randomized Phase II Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Photofrin</intervention_name>
    <description>The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.</description>
    <arm_group_label>A single arm, non-randomized Phase II Study</arm_group_label>
    <other_name>Porfimer Sodium, Photofrin,photosensiter,dye</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological diagnosis of bladder cancer, non muscle invasive&#xD;
&#xD;
          -  Recurrent after at least one course of standard intravesical therapy after&#xD;
             transurethral resection (TURBT).&#xD;
&#xD;
          -  Maximum debulking of tumor by TURBT/fulguration&#xD;
&#xD;
          -  One or more of the following:&#xD;
&#xD;
               -  Contraindications to conventional intravesical therapy, including patient's&#xD;
                  refusal.&#xD;
&#xD;
               -  Positive or suspicious urine cytology localized to the bladder&#xD;
&#xD;
               -  Prior intravesical therapy and persistent atypia.&#xD;
&#xD;
               -  Premalignant (diffuse squamous metaplasia or malakoplakia) lesions.&#xD;
&#xD;
          -  Bladder capacity greater or equal to 150 cc.&#xD;
&#xD;
          -  No contraindications to an appropriate anesthesia or analgesia.&#xD;
&#xD;
          -  Karnofsky's performance status &gt; 50.&#xD;
&#xD;
          -  Patients must sign an informed consent form in accordance with the Institution's&#xD;
             Review Board and FDA 21 CFR Part 50.&#xD;
&#xD;
          -  Female patients must be practicing a medically acceptable form of birth control or be&#xD;
             sterile or postmenopausal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing mother.&#xD;
&#xD;
          -  Known hypersensitivity to porphyrins.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Unyime O Nseyo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NF/SGVAHS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Malcom Randall NF/SG Veterans Administration Health System</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>May 4, 2006</study_first_submitted>
  <study_first_submitted_qc>May 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2006</study_first_posted>
  <last_update_submitted>October 25, 2012</last_update_submitted>
  <last_update_submitted_qc>October 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>North Florida/South Georgia Veterans Health System</investigator_affiliation>
    <investigator_full_name>Unyime O. Nseyo, MD</investigator_full_name>
    <investigator_title>PHYSICIAN</investigator_title>
  </responsible_party>
  <keyword>Bladder Cancer</keyword>
  <keyword>Photodynamic Therapy</keyword>
  <keyword>Photofrin</keyword>
  <keyword>Photosensitization</keyword>
  <keyword>Photoradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihematoporphyrin Ether</mesh_term>
    <mesh_term>Hematoporphyrin Derivative</mesh_term>
    <mesh_term>Trioxsalen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

